Cardiology Topic Homepage

Learning Zones

,Oral Header image

The Oral Anticoagulation Reversal Knowledge Centre is intended to provide healthcare professionals with accurate information on the approaches to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding, or require surgery. 

Content is arranged within the following sections:

  • Disease management: referenced and illustrated information on blood coagulation, bleeding risks with anticoagulation and management of these risks
  • Oral anticoagulants: information on oral vitamin K antagonists (VKAs) and non-vitamin K oral anticoagulants (NOACs)
  • Publications digest: expert commentary of relevant recently published articles
  • Symposia and congresses: presentation slides and videos taken from sponsored satellite symposia at ISICEM 2016 and ISTH/ISICEM 2015 
  • Resources: links to key papers, phase III trial slides and an upcoming events calendar


Register for FREE today for full access to this resource.

This resource is developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with content provided by CSL Behring.

This resource is not intended for healthcare professionals outside Europe.

KCT16-02-0017

,Adipositas-Lernzentrum

Das Adipositas-Lernzentrum enthält klinische Informationen und Materialien für Gesundheitsexperten, die mit der Behandlung und dem Management von adipösen oder übergewichtigen Patienten befasst sind.

Hier finden Sie ein Wissenszentrum mit Informationen über die Epidemiologie, Pathophysiologie, klinischen Leitlinien, Bewertungs- und Behandlungsoptionen, Präventionsmethoden u. v. m. Andere Bereiche des Lernzentrums beinhalten eine Bibliothek klinischer Medien, neueste Nachrichten und Artikel aus Fachzeitschriften, Informationen über Veranstaltungen, Leitfäden für Patienten sowie die EACCME-akkreditierte CME-Reihe der europäischen Adipositas-Initiative, mit der insgesamt fünf europäische CME-Fortbildungspunkte (ECMECs) erworben werden können.

,Obesity learning hub header ES

El Centro de aprendizaje sobre obesidad contiene información clínica y recursos para profesionales sanitarios que intervienen en el tratamiento y el manejo de pacientes con obesidad o sobrepeso.
Aquí encontrará un Centro de conocimientos con información sobre epidemiología, fisiopatología, directrices clínicas, opciones de tratamiento y evaluación, métodos de prevención y más. Otras secciones del Centro de aprendizaje incluyen una mediateca clínica, noticias y artículos de revistas, información sobre eventos, guías para pacientes y una serie de EMC de la Iniciativa Europea para la Obesidad acreditada por el EACCME que equivale a un total de cinco créditos de EMC europeos.
 

,

Qui troverai un Centro didattico con informazioni su epidemiologia, patofisiologia, linee guide cliniche, opzioni terapeutiche e di valutazione, metodi di prevenzione e tanto altro. Le altre sezioni del Centro di apprendimento comprendono una mediateca clinica, notizie e articoli di giornali, informazioni su eventi, guide per i pazienti e la serie CME European Obesity Initiative accreditata dall’EACCME che vale un totale di cinque crediti ECM europei (ECMEC).

,Obesity LH Portuguese header

​A Plataforma de Aprendizagem sobre Obesidade contém informações clínicas e recursos para profissionais de saúde envolvidos no tratamento e na gestão de doentes obesos ou com excesso de peso.

Encontrará aqui um Centro de Conhecimento com informações sobre epidemiologia, patofisiologia, orientações clínicas, opções de avaliação e tratamento, métodos de prevenção e mais. Outras secções da Plataforma de Aprendizagem incluem uma mediateca clínica, notícias e artigos de publicações especializadas, informações sobre eventos, guias do doente e a série de FMC da Iniciativa Europeia sobre Obesidade, acreditada pelo EACCME, que equivale a um total de cinco créditos europeus de FMC (ECMEC).
,

The Anticoagulation Video Channel* is intended for primary care practitioners and specialists involved in the treatment and follow up care of patients with atrial fibrillation (AF) or venous thromboembolism (VTE). It provides an overview of how to prevent stroke and systemic embolism in nonvalvular AF patients and how to prevent and treat VTE.

Users can expect to find the following videos readily available on the video channel with regular updates:

  • The benefits of dabigatran in preventing stroke in atrial fibrillation patients
    (Hans-Christoph Diener, Gregory YH Lip and John Eikelboom)
  • Dabigatran for the treatment and prevention of DVT and PE
    (Samuel Z Goldhaber)
  • The safety profile of dabigatran
    (Hans-Christoph Diener, John Eikelboom and Jeffrey Weitz)

Healthcare professionals should return often to avoid missing out on new content.

*The Anticoagulation Video Channel has been supported by an educational grant from Boehringer Ingelheim, who provided the videos, and is intended for healthcare professionals outside the USA, Canada and UK.

,Obesity Learning Hub

The Obesity Learning Hub contains clinical information and resources for healthcare professionals involved in obesity treatment and ongoing care. Here you will find a Knowledge Centre covering important disease awareness topics including epidemiology, pathophysiology, assessment, treatment options and prevention methods. The Knowledge Centre section has been independently reviewed for clinical accuracy by Professor Carel Le Roux

Other sections within the Learning Hub include:

  • Events information and congress highlights, including abstract reviews from ICO 2016
  • Featured topics are articles written specifically for this resource on obesity and key related topics
  • The EACCME-accredited European Obesity Initiative CME series, which is worth a combined total of five CME credits
  • A clinical media library containing news, clinical trial information and journal articles
  • For your patient’ downloadable guides, links to support groups and a fitness planner
  • A resources section containing summarised guidelines and case reports detailing suitable management strategies for obese patients

Ensure you return to this resource often to make the most of the regular updates, including 2016 congress highlights from EOS, EASD and Obesity Week.

,

This educational resource contains a range of content developed for healthcare professionals based in Europe who are involved in the treatment and management of type 2 diabetes mellitus. In this section you will find:

Type 2 Diabetes Mellitus Knowledge Centre: Provides epidemiology statistics, current diagnostic criteria from WHO and ADA, treatment options and a section containing the latest guidelines.

Therapy Focus: Compiles material on emerging insulin/incretin treatment combinations arranged across five informative sections.

Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin CME activityEACCME-accredited CME activity worth 1 European CME credit (ECMEC).

‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’ CME activityincludes an expert panel discussion video.

,Obesity series

This EACCME-accredited obesity CME series contains three CME modules, which are ideal for healthcare professionals looking to improve their understanding of obesity as a serious medical illness.

Module 1 – Understanding Obesity
Learn more about obesity as a serious and complex medical illness including comorbidities and complications, the complex factors that influence its development and the cornerstones of an effective weight-management strategy.

Module 2 – Considerations for Individualising Pharmacotherapy
Learn about the complexities of obesity, appropriate use of pharmacotherapy for weight management and how to individualise patient care.

Module 3 – Rationale for Lifelong Behaviour Change
Explore the factors affecting maintenance of weight loss, the importance of implementing permanent behaviour changes to prevent weight regain and the components of a successful long-term weight-management strategy.

Upon successful completion of these modules, participants will receive a combined total of five European CME credits (ECMECs).

Clinical Case Studies

Vascular Graft Infection

Infection: Cardiovascular Infections

Stephanie J. Dancer BSc, MB BS, MSc, MD, FRCPath, DTM&H, Consultant Microbiologist, NHS Lanarkshire, Scotland

Case History
A 72-year-old man was referred by his general practitioner complaining of intermittent pain in the legs on exercise.

MRSA Endocarditis

Infection: Cardiovascular Infections

Christopher D. Pfeiffer, Clinical Fellow, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
Vance Fowler, Associate Professor and Infectious Diseases, Specialist, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA

Case History
A 64-year-old female presented with three weeks of progressive dyspnoea, nausea and vomiting.

Latest News

Medical Videos

Advances in Dual Antiplatelet Therapy for Acute Coronary Syndrome (ACS)
Advances in Dual Antiplatelet Therapy for Acute Coronary Syndrome (ACS)
Animation: New therapy prevents heart failure
Animation: New therapy prevents heart failure
A Guide to the Coronary Angioplasty Procedure
A Guide to the Coronary Angioplasty Procedure
The Lead: Time to Abandon LDL Treatment Targets?
The Lead: Time to Abandon LDL Treatment Targets?
A Discussion of Interventional Cardiology and the Procedures Involved
A Discussion of Interventional Cardiology and the Procedures Involved
3D Medical Animation - Congestive Heart Failure
3D Medical Animation - Congestive Heart Failure

Recent Drug Updates

Medical Journal Abstracts on Cardiology

Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal

Mon 25 Apr 2016 -  Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal

Vitamin K antagonists (VKAs), most commonly warfarin, are a widely prescribed class of drug used as a therapeutic or prophylactic treatment against thrombotic diseases. Reversal of VKAs is necessary ...

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy.

Tue 05 Apr 2016 -  Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy.

Background: Azilsartan (AZI) is a relatively new angiotensin receptor blocker available for the treatment of any stage of hypertension, which was eventually given in combination with chlorthalidone ...

Clinical Guidelines

2016 European Guidelines on cardiovascular disease prevention in clinical practice

May 2016

The present guidelines represent an evidence-based consensus of the 6th European Joint Task..

... Force  involving 10 professional societies.This document has been developed to support healthcare professionals communicating with individuals about their cardiovascular (CV) risk and the benefits of a healthy lifestyle and early modification of their CV risk. In addition, the guidelines provide tools for healthcare professionals to promote population-based strategies and integrate these into national or regional prevention frameworks and to translate these in locally delivered healthcare services, in line with the recommendations of the World Health Organization (WHO) global status report on non-communicable diseases 2010.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

May 2016

The aim of this document is to provide practical, evidence-based guidelines for the diagnosis and..

... treatment of HF. The principal changes from the 2012 guidelines relate to:

I. a new term for patients with HF and a left ventricular ejection fraction (LVEF) that ranges from 40 to 49% — ‘HF with mid-range EF (HFmrEF)’; we believe that identifying HFmrEF as a separate group will stimulate research into the underlying characteristics, pathophysiology and treatment of this population;
II. clear recommendations on the diagnostic criteria for HF with reduced EF (HFrEF), HFmrEF and HF with preserved EF (HFpEF);
III. a new algorithm for the diagnosis of HF in the non-acute setting based on the evaluation of HF probability;
IV. recommendations aimed at prevention or delay of the development of overt HF or the prevention of death before the onset of symptoms;
V. indications for the use of the new compound sacubitril/valsartan, the first in the class of angiotensin receptor neprilysin inhibitors (ARNIs);
VI. modified indications for cardiac resynchronization therapy (CRT);
VII. the concept of an early initiation of appropriate therapy going along with relevant investigations in acute HF that follows the ‘time to therapy’ approach already well established in acute coronary syndrome (ACS);
VIII. a new algorithm for a combined diagnosis and treatment approach of acute HF based on the presence/absence of congestion/hypoperfusion.

Online CME

Considerations for Individualising Pharmacotherapy

Learn about the complexities of obesity, appropriate use of pharmacotherapy for weight management and how to individualise patient care. EACCME accredited.

Understanding Obesity

Learn more about obesity as a serious and complex medical illness including comorbidities and complications, the complex factors that influence its development and the cornerstones of an effective weight-management strategy....

Rationale for Lifelong Behavioural Change

Explore the factors affecting maintenance of weight loss, the importance of implementing permanent behaviour changes to prevent weight regain and the components of a successful long-term weight-management strategy. EACCME accredited.

Clinical Trials

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (PIONEER 6)

Fri 01 Jul 2016

This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 ...

PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

Fri 01 Jul 2016

Obesity and its adverse cardiometabolic consequences are major public health problems. Several features of obesity contribute to the associated cardiovascular risk and are potential targets for ...

Back to top